GlassScriptPhysician profile
Thea A Davis
NPI 1508335159
$13,958.80
in general payments reported to CMS, 2019-2025
32 companies · $2,054 in 2025
The $2,054 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,478 · 2022: $3,997 · 2023: $2,264 · 2024: $2,167 · 2025: $2,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,464 · Education: $20.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,463.59 |
| Education | $20.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,407.14 | 2021-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $2,331.72 | 2021-2025 | |
| Ucb, INC. | $1,492.47 | 2021-2025 | Cimzia, Bimzelx |
| Alexion Pharmaceuticals, INC. | $1,134.74 | 2021-2025 | Strensiq |
| Lilly USA, LLC | $742.21 | 2021-2025 | Taltz |
| Novartis Pharmaceuticals Corporation | $738.03 | 2021-2025 | |
| Janssen Biotech, INC. | $615.40 | 2021-2025 | Tremfya |
| Pfizer INC. | $585.35 | 2021-2025 | |
| Glaxosmithkline, LLC. | $344.24 | 2021-2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $329.83 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $305.09 | 2022-2025 | Orencia |
| Radius Health, INC. | $284.59 | 2021-2025 | Tymlos |
| Horizon Therapeutics Plc | $170.52 | 2021-2023 | Krystexxa |
| Organon LLC | $165.34 | 2023-2025 | Renflexis, Hadlima, Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.54 | 2021-2025 | Cyltezo, Spevigo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $155.66 | 2022-2025 | Acthar |
| Genentech USA, INC. | $143.93 | 2021-2025 | Actemra, Rituxan |
| Genzyme Corporation | $115.86 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $100.87 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $88.60 | 2022 | |
| Octapharma USA, INC. | $64.77 | 2025 | Octagam Immune Globulin (Human) |
| Almatica Pharma LLC | $60.90 | 2025 | Teriparatide |
| Fresenius Kabi USA, LLC | $60.78 | 2023 | Idacio |
| Sobi, INC | $57.50 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $56.89 | 2021-2023 | Euflexxa |
| Actelion Pharmaceuticals US, INC. | $55.67 | 2023-2024 | Uptravi, Opsumit |
| Ani Pharmaceuticals, INC. | $46.10 | 2022 | |
| Fidia Pharma USA INC. | $42.93 | 2025 | Hymovis |
| Janssen Pharmaceuticals, INC | $41.29 | 2021 | |
| Pacira Therapeutics, INC. | $23.49 | 2021 | |
| Celltrion USA INC. | $20.42 | 2023 | Yuflyma |
| Hikma Pharmaceuticals USA | $17.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thea Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.